{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:31:32Z","timestamp":1788777092478,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003321","name":"Queen's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.clml.2020.04.014","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T04:11:45Z","timestamp":1588219905000},"page":"e791-e800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7692-1947","authenticated-orcid":false,"given":"Bethany E.","family":"Monteith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Venner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna E.","family":"Reece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Kew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lalancette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn S.","family":"Garland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-1621","authenticated-orcid":false,"given":"Lois E.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Pater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-3390","authenticated-orcid":false,"given":"Annette E.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.04.014_bib1","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1182\/blood-2018-99-117824","article-title":"A\u00a0single-arm phase II study of high-dose weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed multiple myeloma after 1-3 prior therapies","volume":"132","author":"Venner","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.014_bib2","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/j.clml.2019.09.449","article-title":"Unusual carfilzomib toxicity: three cases of drug-induced thrombotic microangiopathy (TMA) after treatment with high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone (wCCD)","volume":"19","author":"Monteith","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.04.014_bib3","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc N Y Pathol Soc"},{"key":"10.1016\/j.clml.2020.04.014_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0002-9343(52)90022-3","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease","volume":"13","author":"Moschcowitz","year":"1952","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2020.04.014_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.1962.tb06541.x","article-title":"Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis","volume":"8","author":"Brain","year":"1962","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.04.014_bib6","series-title":"Current Medical Diagnosis & Treatment 2019","article-title":"Blood Disorders","author":"Damon","year":"2019"},{"key":"10.1016\/j.clml.2020.04.014_bib7","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.04.014_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/brain\/79.3.511","article-title":"Thrombotic microangiopathy (thrombotic thrombocytopenic purpura) associated with acute haemorrhagic leucoencephalitis and sensitivity to oxophenarsine","volume":"79","author":"Symmers","year":"1956","journal-title":"Brain"},{"key":"10.1016\/j.clml.2020.04.014_bib9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.014_bib10","first-page":"14","article-title":"Acute intravascular haemolysis due to quinine","volume":"91","author":"Webb","year":"1980","journal-title":"N\u00a0Z Med J"},{"key":"10.1016\/j.clml.2020.04.014_bib11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.04.014_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0272-6386(99)70269-6","article-title":"Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome","volume":"33","author":"Glynne","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clml.2020.04.014_bib13","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1053\/j.ajkd.2010.06.006","article-title":"The role of endothelial cell injury in thrombotic microangiopathy","volume":"56","author":"Goldberg","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clml.2020.04.014_bib14","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/j.1600-6143.2005.01047.x","article-title":"Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys","volume":"5","author":"Sartelet","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2020.04.014_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcade) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clml.2020.04.014_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.12-1-11","article-title":"Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases","volume":"12","author":"Francis","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.04.014_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-0609.2010.01448.x","article-title":"Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration","volume":"85","author":"Elliott","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.04.014_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clml.2020.04.014_bib19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ajh.21646","article-title":"TTP disease course is independent of myeloma treatment and response","volume":"85","author":"Hofmeister","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.04.014_bib20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/MBC.0b013e32830610ee","article-title":"Thrombotic thrombocytopenic purpura associated with multiple myeloma","volume":"19","author":"Alpay","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.clml.2020.04.014_bib21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5414\/CN107579","article-title":"Thrombotic thrombocytopenic purpura due to anti-ADAMTS13 antibodies in multiple myeloma","volume":"81","author":"Yao","year":"2014","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.clml.2020.04.014_bib22","first-page":"1","article-title":"Renal thrombotic microangiopathy associated with the use of bortezomib in a patient with multiple myeloma","volume":"2016","author":"Van Keer","year":"2016","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.clml.2020.04.014_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12185-008-0140-1","article-title":"Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma","volume":"88","author":"Morita","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2020.04.014_bib24","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.4081\/hr.2012.e13","article-title":"Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma","volume":"4","author":"Salmenniemi","year":"2012","journal-title":"Hematol Rep"},{"key":"10.1016\/j.clml.2020.04.014_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-006461","article-title":"Bortezomib-induced thrombotic thrombocytopaenic purpura","volume":"2012","author":"Mehta","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clml.2020.04.014_bib26","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3109\/10428194.2014.977887","article-title":"Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma","volume":"56","author":"Chan","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.04.014_bib27","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.04.014_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.transci.2016.03.002","article-title":"Carfilzomib: a cause of drug-associated thrombotic microangiopathy","volume":"54","author":"Qaqish","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.clml.2020.04.014_bib29","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1038\/bcj.2016.62","article-title":"Thrombotic microangiopathy during carfilzomib use: case series in Singapore","volume":"6","author":"Chen","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.04.014_bib30","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/ccr3.1214","article-title":"Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment","volume":"5","author":"Gosain","year":"2017","journal-title":"Clin Case Reports"},{"key":"10.1016\/j.clml.2020.04.014_bib31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.clml.2020.04.014_bib32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2369-15-156","article-title":"Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma","volume":"15","author":"Hobeika","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.clml.2020.04.014_bib33","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.04.014_bib34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.04.014_bib35","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2020.04.014_bib36","doi-asserted-by":"crossref","first-page":"LBA-6","DOI":"10.1182\/blood-2019-132629","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): primary analysis results from the randomized, open-label, phase 3 study Candor (NCT03158688)","volume":"134","author":"Usmani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.014_bib37","series-title":"Amgen Product Monograph for Kyprolis \/ carfilzomib for\u00a0injection, Revision February 21, 2020","year":"2020"},{"key":"10.1016\/j.clml.2020.04.014_bib38","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.1002\/ajh.24662","article-title":"Ixazomib-induced thrombotic microangiopathy","volume":"92","author":"Yui","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.04.014_bib39","first-page":"7063145","article-title":"Case report: drug-induced thrombotic microangiopathy due to cumulative toxicity of ixazomib","volume":"2018","author":"Atallah-Yunes","year":"2018","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.clml.2020.04.014_bib40","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1445-5994.2011.02458.x","article-title":"Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib","volume":"41","author":"Moore","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.clml.2020.04.014_bib41","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1182\/blood.V120.21.5037.5037","article-title":"Fatal thrombotic microangiopathy developing within 24 hours of carfilzomib in a patient with relapsed multiple myeloma (MM)","volume":"120","author":"Atrash","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.014_bib42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jca.21371","article-title":"Carfilzomib-associated thrombotic microangiopathy initially treated with therapeutic plasma exchange","volume":"30","author":"Sullivan","year":"2015","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.clml.2020.04.014_bib43","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.clml.2020.01.016","article-title":"Case report: carfilzomib-induced thrombotic microangiopathy with complement activation treated successfully with eculizumab","volume":"20","author":"Bhutani","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.04.014_bib44","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","article-title":"Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells","volume":"66","author":"Roccaro","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2020.04.014_bib45","doi-asserted-by":"crossref","first-page":"143426","DOI":"10.1155\/2014\/143426","article-title":"Anti-VEGF cancer therapy in nephrology practice","volume":"2014","author":"Izzedine","year":"2014","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.clml.2020.04.014_bib46","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bjh.13993","article-title":"Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura","volume":"173","author":"Patriquin","year":"2016","journal-title":"Br J Hematol"},{"key":"10.1016\/j.clml.2020.04.014_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.04.014_bib48","first-page":"9681832","article-title":"Remission of severe, relapsed, and refractory TTP after multiple cycles of bortezomib","volume":"2017","author":"Pandey","year":"2017","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.clml.2020.04.014_bib49","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bjh.12696","article-title":"Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura","volume":"164","author":"Mazepa","year":"2013","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.04.014_bib50","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2019-122637","article-title":"Overall and progression free survival from the Mcrn-003\/Myx.1 trial: a single arm phase II study of high-dose weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed multiple myeloma","volume":"134","author":"Venner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.014_bib51","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2015-11-683854","article-title":"CHAMPION-1: a phase 1\/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"127","author":"Berenson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.014_bib52","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2014-02-556308","article-title":"A\u00a0phase 2 single-center study of carfilzomib 56 mg\/m2 with or without low-dose dexamethasone in relapsed multiple myeloma","volume":"124","author":"Lendvai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.014_bib53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood-2014-03-563759","article-title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study","volume":"124","author":"Bringhen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.014_bib54","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.clml.2020.04.014_bib55","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1200\/JCO.2017.35.15_suppl.8003","article-title":"Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM)","volume":"35","author":"Gay","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.04.014_bib56","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Transp"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:26Z","timestamp":1761870926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020302093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2152265020302093"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}